San Francisco Luncheon with Heather Mac Donald (SOLD OUT)

March 7, 2018
500 California Street, San Francisco, CA, USA
150320221647327704

How Campus Victimology is Remaking the “Real World”

Featuring Q&A Session with PRI Senior Fellow Dr. Steven F. Hayward

The Pacific Research Institute invites you to a special noon luncheon with Heather Mac Donald, the Thomas W. Smith Fellow at the Manhattan Institute and a contributing editor to City Journal. Mac Donald will discuss the latest assaults on free speech both within the academy and outside of it. She will explain the causes of the growing censorship and suggest how to combat it.

Wednesday, March 7, 2018
Noon Luncheon

Omni San Francisco
500 California Street
San Francisco, CA 94104

Luncheon Ticket: $60
Sir Antony Fisher Freedom Society & YLC Members: $30

For more information, please contact Vickie Nelson, Director of Events, at
(415) 955-6110 or [email protected].

***SOLD OUT***

Registration is closed for this event.

Mac Donald, a recipient of the 2005 Bradley Prize, has written extensively on how race-based attacks on the criminal justice system by Black Lives Matter and other groups are undermining the authority of law and putting lives at risk. Her recent speeches at UCLA and Claremont McKenna College were disrupted by protesters.

Tell Your Friends

Related

FreeCitiesBook10 Insurance web

California’s home insurance market: Political trouble on the horizon

California’s long-distorted insurance market reached a level of dysfunction in 2023 that had tangible consequences for average homeowners. Following a series of costly wildfires, they ...
NextRoundSquare1600L NoBranding

Close Races for Key Statewide Ballot Measures

This week, Tim and Matt discuss the latest statewide poll showing close races for the wealth tax and CEQA reform. They also discuss Gov. Newsom’s ...
pharmaceutical warehouse.

The GLP-1 Shortage Is Over. Mass-Market Compounding Should Be, Too

The U.S. Food and Drug Administration’s effort to rein in mass-market copies of blockbuster GLP-1 drugs just survived a major legal challenge. Last month, the ...
Scroll to Top